EGFR and neoplasm: Additionally, EGFR activation has been implicated in reducing lenvatinib efficacy [10–12], as supported by a small clinical trial where the combination of an EGFR inhibitor with lenvatinib elicited a dramatic anti-tumour response and reversed TKI resistance [12].